Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 141 to 150 of 2581 total matches.

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
Drugs for Treatment and Prevention of Venous Thromboembolism ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Three New Drugs for Hereditary Angioedema

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2010  (Issue 1345)
Three New Drugs for Hereditary Angioedema ...
In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.
Med Lett Drugs Ther. 2010 Aug 23;52(1345):66-7 |  Show IntroductionHide Introduction

Drugs for Acute Spinal Cord Injury

   
The Medical Letter on Drugs and Therapeutics • Aug 06, 1993  (Issue 902)
Drugs for Acute Spinal Cord Injury ...
The well-publicized recovery from paralysis of a professional football player has recently focused attention on the growing use of drugs to minimize the effects of spinal cord injury. Methylprednisolone sodium succinate (Solu-Medrol - Upjohn), commercially available in the USA for intravenous treatment of transplant rejection and various inflammatory and auto-immune disorders, and GM-1 ganglioside, commercially available in Italy (Sygen - Fidia) but not in the USA, are now widely used in patients with spinal cord injury.
Med Lett Drugs Ther. 1993 Aug 6;35(902):72-3 |  Show IntroductionHide Introduction

Drugs for Vomiting Caused by Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 1993  (Issue 912)
Drugs for Vomiting Caused by Cancer Chemotherapy ...
Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.
Med Lett Drugs Ther. 1993 Dec 24;35(912):124-6 |  Show IntroductionHide Introduction

Drugs for Common Bacterial Infections in Adults

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 2017  (Issue 1532)
Drugs for Common Bacterial Infections in Adults ...
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse...
Med Lett Drugs Ther. 2017 Oct 23;59(1532):171-7 |  Show IntroductionHide Introduction

Choice of Drugs for Heparin-Induced Thrombocytopenia

   
The Medical Letter on Drugs and Therapeutics • May 28, 2012  (Issue 1391)
Choice of Drugs for Heparin-Induced Thrombocytopenia ...
A reader has asked us to review the choice of drugs for heparin-induced thrombocytopenia (HIT), a prothrombotic state with high morbidity and mortality. Three recent publications have made somewhat different recommendations on its treatment.
Med Lett Drugs Ther. 2012 May 28;54(1391):43-4 |  Show IntroductionHide Introduction

Rosuvastatin - a New Lipid-lowering Drug

   
The Medical Letter on Drugs and Therapeutics • Oct 13, 2003  (Issue 1167)
Rosuvastatin - a New Lipid-lowering Drug ...
Rosuvastatin (Crestor - AstraZeneca), an HMG-CoA reductase inhibitor (or "statin"), was recently approved by the FDA for lowering serum cholesterol and triglyceride concentrations and raising HDL cholesterol levels. Rosuvastatin, like other statins, inhibits the enzyme that catalyzes the rate-limiting step in cholesterol synthesis, but it is claimed to be more potent than the others. All of these drugs must be taken indefinitely; if they are discontinued, lipid levels return to baseline.
Med Lett Drugs Ther. 2003 Oct 13;45(1167):81-3 |  Show IntroductionHide Introduction

Correction: Drugs for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017  (Issue 1529)
Correction: Drugs for Helicobacter pylori Infection ...
In Table 3 on page 116 (Med Lett Drugs Ther 2017; 59:113), the price provided for Prevpac was for a 14-day supply, rather than for a 10-day supply as stated in footnote 1. The footnote has been corrected and the price of the generic formulation of Prevpac has been added.
Med Lett Drugs Ther. 2017 Sep 11;59(1529):154 |  Show IntroductionHide Introduction

Drugs and Vaccines Against Biological Weapons

   
The Medical Letter on Drugs and Therapeutics • Oct 15, 2001  (Issue 1115)
Drugs and Vaccines Against Biological Weapons ...
Concerns have arisen anew about possible use of biological weapons. The pathogens considered most likely to be used for this purpose are discussed in this article. A good source for additional information is www.usamriid.army.mil/education/bluebook.html.
Med Lett Drugs Ther. 2001 Oct 15;43(1115):87-9 |  Show IntroductionHide Introduction

Drugs for Acute Otitis Media in Children

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
Drugs for Acute Otitis Media in Children ...
More antibiotics are prescribed for treatment of acute otitis media (AOM) than for any other infection in young children. Children with AOM typically present with otalgia, fever, and bulging and erythema of the tympanic membrane.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):22-3 |  Show IntroductionHide Introduction